Credit Suisse Assumes Viridian Therapeutics at Outperform, Announces Price Target of $51
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Tiago Fauth assumes Viridian Therapeutics (NASDAQ:VRDN) with an Outperform rating and announces a price target of $51.
June 14, 2023 | 9:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Credit Suisse assumes Viridian Therapeutics with an Outperform rating and a price target of $51.
The Outperform rating and price target of $51 by Credit Suisse analyst Tiago Fauth indicate a positive outlook for Viridian Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100